89-zr-dfo-star
Small moleculeexperimentalImaging agent
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 2, 2025 (NCT06894745)
Timeline
2020s
- Jan 1, 2025
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
- Imaging
- 89-zircon
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06894745 | Phase 1 | Jun 2, 2025 | National Cancer Institute (NCI), ProLynx LLC, University of California, San Francisco |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2025 |
| ProLynx LLC | For profit | 1 | 0 | 1 | 2025 |
| University of California, San Francisco | Academic/Hospital | 1 | 1 | 1 | 2025 |
3 organizations
Page 1 / 1